Biosimilar Focus STC Biologics specializes in biologics process development and biosimilar development, presenting a clearPath for collaboration with pharma/biotech partners seeking to accelerate biosimilar programs and IND/CTA submissions.

Analytics Driven With expertise in analytics driven process development, STC offers potential value in analytical method development, process characterization, and quality by design support to reduce development risk and speed up IND/MAA filings.

Speed-To-Clinic Leverage STC’s Speed-To-Clinic Platform for monoclonal antibodies to move from royalty-free cell lines to cGMP manufacturing with released drug substance in as little as twelve months, appealing to teams seeking rapid clinic-ready alternatives.

Strategic Partnerships Existing emphasis on partnering with pharmaceutical and biotech companies to expedite drug development indicates ripe opportunities for outsource partnerships, capacity support, and risk-sharing collaborations in analytical and process development.

Clinical Collaboration Recent manufacturing partnership for TZLS-501 in Covid-19 patients demonstrates STC’s capability to support clinical programs and scalable manufacturing, suggesting opportunities for joint development and supply agreements in infectious disease and biosimilar indications.